In this issue:
Adjuvant denosumab in hormone receptor-positive breast cancer
Ramucirumab for metastatic gastric or junctional adenocarcinoma
Ramucirumab after sorafenib in advanced hepatocellular carcinoma
Patient-reported outcomes with nivolumab + ipilimumab vs sunitinib for RCC
Pembrolizumab vs platinum-based chemotherapy for advanced NSCLC
Glembatumumab vedotin for advanced melanoma
Pregnancies during/after trastuzumab and/or lapatinib in patients with breast cancer
Cost-effectiveness of durvalumab consolidation therapy for stage III NSCLC
Durvalumab + tremelimumab in head and neck SCC
Capecitabine + bevacizumab cost-effectiveness for metastatic colorectal cancer
Please login below to download this issue (PDF)